Except for active lymphocytes, other normal blood cells seldom express CD26, implying that targeting CD26 may represent a viable strategy for eliminating CML-LSCs [11, 12]. This evidence concerns the gene DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive.